

■ SUPPLEMENTARY INFORMATION




Fig. S1. Fluorescence microscopic images of Jurkat and A3.01 cells treated with (a) naked siRNA, (b) chitosan/siRNA nanoparticles, and (c) 20% scFvCD7-chitosan/siRNA nanoparticles. (d) Cells were also pretreated with soluble scFvCD7 before treatment with 20% scFvCD7-chitosan/siRNA nanoparticles (scale bar, 20 μ m). FITC-labeled siRNA was used for visualization ([siRNA] = 200 pmol/well).




Fig. S2. Cellular association of Lipofectamine (green solid line), unmodified-chitosan (blue dashed line), and 20% scFvCD7-chitosan (red solid line) nanoparticles with (a) HeLa and (b) HEK 293FT cells determined by flow cytometry. Filled histogram indicates untreated cells as a control. (c) Quantitative analysis of cellular association of chitosan-based nanoparticles with HeLa (filled bars) and HEK 293FT (empty bars) cells ([FITC-siRNA] = 200 pmol/well).




Fig. S3. Binding between phycoerythrin-labeled anti-CD7 antibody and CD7 receptors on (a) Jurkat, (b) HeLa, and (c) HEK 293FT cells identified by flow cytometry.